ArticleBlood advances2020

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.

Diego Villa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.